Elena Bonora1, Francesca Bianco1,2, Roberto De Giorgio3. 1. Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy. 2. Department of Veterinary Medical Sciences, University of Bologna, Italy. 3. Department of Translational Medicine, St. Anna Hospital, University of Ferrara, Italy.
TO THE EDITOR: We read with great interest the article “A novel cohesinopathy causing chronic intestinal pseudo obstruction in 2 siblings and literature review” by Venkatesh et al[1] reporting on a gene mutation in 2 patients with a clinical phenotype of chronic intestinal pseudo-obstruction (CIPO). The topic of the genetic analysis in rare forms of severe gut dysmotility is extremely cogent in the neurogastroenterology area especially because the management of CIPO is still largely ineffective and mainly centered on general measures (hydro-electrolyte balance and adequate caloric support often via parenteral nutrition). Thus, investigating genetic and molecular mechanisms may unveil novel therapeutic approaches for this orphan disorder. In any affected patient, either adult or pediatric, CIPO is characterized by a marked derangement of gut propulsion, mimicking a mechanical sub-occlusion, in the absence of any anatomical cause of obstruction. The severity of the clinical presentation is typically associated with disabling digestive symptoms, which contribute to poor quality of life and increased mortality. In the last years, several genetic causes have been identified in different subsets of CIPO patients. Heterozygous mutations in the ACTG2 gene were found in patients with CIPO characterized by degeneration of enteric smooth muscle, as well as in the “megacystis, microcolon, and intestinal hypoperistalsis” syndrome.[2-5] X-linked CIPO has been ascribed to filamin A gene mutations.[6,7]
TYMP, POLG, and LIG3 genes have been demonstrated in recessive forms of mitochondrial CIPO.[8-10] Finally, homozygous mutations in SGOL1 and RAD21 genes, encoding for members of the cohesin complex, have been identified in another subset of CIPO in association with additional clinical manifestations, ie, chronic atrial and intestinal dysrhythmia (CAID),[11] or cardiac defect and long Barrett esophagus in Mungan’s syndrome,[12,13] respectively. Both SGOL1 and RAD21 mutations are known to be causative of these 2 forms of “cohesinopathy” underlying CIPO.In this context, Venkatesh et al[1] identified a homozygous variant in SGOL1 in 2 siblings using next-generation sequencing analysis. The mutation was correctly interpreted to be causative, although the authors did not inform whether a target gene panel analysis, whole exome or whole genome sequencing was performed. These methodological approaches are of critical importance to exclude the presence of other putative variants of interest. Moreover, the identified variant (p.Lys23Glu) is exactly the same of that reported by Chetaille et al[11] who showed a causative homozygous variant in several Canadian pedigrees with patients affected by CIPO and atrial dysrhythmia (hence CAID, as previously mentioned). We address this in order to avoid possible misinterpretation by the reader. It would be always important to report the genomic coordinates and the dbSNP ID of a variant, as in the current case (rs199815268). This finding facilitates comparison between studies and can help identifying clinical convergence and/or differences among CIPO patients. Furthermore, the segregation of the selected variants should be pursued when possible in order to confirm that the pattern(s) of inheritance is/are correct. Since there was no report of consanguinity in the family reported by Venkatesh et al,[1] it would be very important to prove that both parents were heterozygous carriers, maybe again due to a founder effect in the corresponding geographical area, as observed in the original paper by Chetaille et al[11] in the described Canadian families.In conclusion, we commend Venkatesh et al[1] for their effort aimed at identifying CIPO-causative variants, which is a pivotal approach to better understand the molecular defects underlying this difficult and highly challenging condition. However, data regarding mutations of any detected variants should be carefully detailed to provide a clear-cut understanding for all readers.
Authors: Heli J Lehtonen; Taina Sipponen; Sari Tojkander; Riitta Karikoski; Heikki Järvinen; Nigel G Laing; Pekka Lappalainen; Lauri A Aaltonen; Sari Tuupanen Journal: Gastroenterology Date: 2012-09-06 Impact factor: 22.682
Authors: Gert Van Goethem; Marianne Schwartz; Ann Löfgren; Bart Dermaut; Christine Van Broeckhoven; John Vissing Journal: Eur J Hum Genet Date: 2003-07 Impact factor: 4.246
Authors: Michael F Wangler; Claudia Gonzaga-Jauregui; Tomasz Gambin; Samantha Penney; Timothy Moss; Atul Chopra; Frank J Probst; Fan Xia; Yaping Yang; Steven Werlin; Ieva Eglite; Liene Kornejeva; Carlos A Bacino; Dustin Baldridge; Jeff Neul; Efrat Lev Lehman; Austin Larson; Joke Beuten; Donna M Muzny; Shalini Jhangiani; Richard A Gibbs; James R Lupski; Arthur Beaudet Journal: PLoS Genet Date: 2014-03-27 Impact factor: 5.917